Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2018 Preparation: PD-1 Predictions And Commercialization Challenges

What's next for the PD-1 market, a cancer therapy area that exploded in 2017 as recently launched products secured ever more approvals? Maria Whitman, managing principal at sales and marketing firm ZS Associates, talks about challenges facing the booming immuno-oncology market and shares her predictions for 2018.

ImmunoOncology Business Strategies Scrip 100

Futurology: Are Mega Mergers A Thing Of The Past?

Bolt-ons or big-ticket buys? As another year passes without a big pharma mega merger despite industry giants sitting on large cash piles, we consider whether 2018 will bring major upheaval in the industry landscape, and where M&A will be most likely to take place.

M & A Scrip 100 Business Strategies

Time Is Running Out For Industry To Prepare For Brexit, Firms Begin to Feel Staffing Effects

Nearly 18 months after the UK voted to leave the European Union, pharmaceutical companies and regulators are still in the dark as to what kind of regulatory arrangements will exist between the two parties after Brexit takes place in March 2019.

Scrip 100 Brexit Human Capital

Future-Proofing Human Capital: Does Biopharma Have The Right Stuff?

Biopharma's future depends entirely on the application of human ingenuity to complex problems with no easy solutions. In Vivo, with its Informa business solutions partner EBD Academy, recently conducted a survey of industry decision-makers in the US and Europe for recommendations on how to attract talent, boost employee engagement, foster diversity and maintain the product innovation that patients demand and society expects.

BioPharmaceutical Leadership Business Strategies

Where Will CNS Drug Development Go In 2018?

The world's expanding, aging population means diseases of the central nervous system, like Alzheimer's and Parkinson's, are potential blockbuster areas for innovative pharma and biotech companies that are able to navigate clinical studies and get to market. Scrip looks at five emerging trends that are likely to affect the CNS drug development landscape in 2018.

Neurology Business Strategies Market Intelligence
Advertisement
UsernamePublicRestriction

Register

Advertisement